ASD-006 oral drug for obesity and metabolic syndrome
ASD-006 is an innovative oral drug developed as a clathrate of HP-alpha-cyclodextrin and capric acid, designed to combat obesity and metabolic syndrome. It aims to improve health outcomes by enhancing intestinal absorption and reducing postprandial glucose levels.
Overview
ASD-006 is a novel oral drug designed to combat obesity and metabolic syndrome, conditions affecting millions globally. Developed as a clathrate of HP-alpha-cyclodextrin (HPaCD) and capric acid (C10), ASD-006 enhances intestinal absorption and targets metabolic markers such as postprandial glucose levels and insulin resistance. Unlike incretin mimetics, which have limited tolerance due to side effects like nausea, ASD-006 offers a better-tolerated alternative with significant health benefits.
Technical specifications
Key features:
- Clathrate Composition: Combines HPaCD, known for its water solubility, and C10, an effective penetration enhancer.
- Mode of Action: Reduces metabolic syndrome markers such as postprandial glucose, insulin resistance, and obesity.
- Safety and Efficacy: Proven safe and effective in randomized controlled trials (RCTs) against various metabolic conditions.
Mechanism of Action:
- Cyclodextrins function by reducing saturated/trans fatty acids and non-essential phospholipids, contributing to improved metabolic health.
Technology readiness level
Currently, ASD-006 is at Technology Readiness Level 6, having been validated in controlled environments and preparing for further FDA discussions to determine subsequent steps for clinical trials.
About ASDERA
ASDERA is a biotechnology company that develops targeted medical interventions by utilizing a patented computational biostatistics platform. This approach identifies complex genetic risk factors that were often considered inconclusive in other studies, particularly within small-scale epidemiological data or previously failed phase 2/3 clinical trials. By analyzing genetic structures and neighborhood hotspots, the company aims to uncover missing heritability and translate these findings into therapeutic candidates for conditions with significant unmet medical needs. ASDERA operates as a virtual organization that outlicenses its patented assets once development milestones are achieved.
The company focuses on therapeutic areas including aging-related health, oncology, and orphan diseases. Its pipeline includes candidates for developmental language disorders in children at risk of autism, lysosomal storage diseases, and metabolic syndrome, as well as nutritional formulations designed as fasting mimetics to improve aging-related processes. ASDERA serves the broader pharmaceutical and healthcare sector by providing a novel method for drug discovery and asset development. Its research has historically addressed various health challenges, including neurodegeneration, cardiovascular health, and infectious disease responses.
Inquire about this partnering listing
Industry applications
delivered to your inbox.